Morand E - Search Results

1

OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set.

Nielsen W, Strand V, Simon LS, Parodis I, Kim AHJ, Desai M, Enman Y, Wallace D, Chaichian Y, Navarra S, Aranow C, MacKay M, Trotter K, Tayer-Shifman OE, Duarte-Garcia A, Shan Tam L, Ugarte-Gil MF, PonsEstel GJ, Reynolds JA, Nikpour M, Hoi A, Romero-Diaz J, Papachristos D, Aggarwal A, Mok CC, Fujio K, Ramsey-Goldman R, Howe A, Kia BN, Bonilla D, Thumboo J, Mosca M, Aringer M, Johnson SR, Drucker AM, Morand E, Bruce I, Touma Z; OMERACT SLE Working Group. Nielsen W, et al. Among authors: morand e. Semin Arthritis Rheum. 2024 Apr;65:152380. doi: 10.1016/j.semarthrit.2024.152380. Epub 2024 Jan 14. Semin Arthritis Rheum. 2024. PMID: 38281467

2

Churg-Strauss syndrome: the use of cyclophosphamide in mononeuritis.

Hoi AY, Morand EF. Hoi AY, et al. Among authors: morand ef. Rheumatology (Oxford). 2003 Feb;42(2):390-1. doi: 10.1093/rheumatology/keg067. Rheumatology (Oxford). 2003. PMID: 12595649 No abstract available.

3

Is macrophage migration inhibitory factor a therapeutic target in systemic lupus erythematosus?

Hoi AY, Morand EF, Leech M. Hoi AY, et al. Immunol Cell Biol. 2003 Oct;81(5):367-73. doi: 10.1046/j.1440-1711.2003.01183.x. Immunol Cell Biol. 2003. PMID: 12969324 Review.

4

Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice.

Hoi AY, Hickey MJ, Hall P, Yamana J, O'Sullivan KM, Santos LL, James WG, Kitching AR, Morand EF. Hoi AY, et al. J Immunol. 2006 Oct 15;177(8):5687-96. doi: 10.4049/jimmunol.177.8.5687. J Immunol. 2006. PMID: 17015758

5

Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases.

Hoi AY, Iskander MN, Morand EF. Hoi AY, et al. Inflamm Allergy Drug Targets. 2007 Sep;6(3):183-90. doi: 10.2174/187152807781696455. Inflamm Allergy Drug Targets. 2007. PMID: 17897055 Review.

6

Smooth muscle myopathy as an underrecognized manifestation of active systemic lupus erythematosus.

Ngian GS, Naidoo P, Morand EF, Hoi AY. Ngian GS, et al. Among authors: morand ef. Intern Med J. 2011 Jun;41(6):495-8. doi: 10.1111/j.1445-5994.2011.02505.x. Intern Med J. 2011. PMID: 21707895

7

Lymphocytes from systemic lupus erythematosus patients display increased spreading on VCAM-1, an effect associated with active renal involvement.

Cheng Q, Hoi A, Hickey MJ, Morand EF. Cheng Q, et al. Among authors: morand ef. Lupus. 2012 May;21(6):632-41. doi: 10.1177/0961203312436860. Epub 2012 Feb 16. Lupus. 2012. PMID: 22345121

8

Asian ethnicity in systemic lupus erythematosus: an Australian perspective.

Connelly K, Morand EF, Hoi AY. Connelly K, et al. Among authors: morand ef. Intern Med J. 2013 Jun;43(6):618-24. doi: 10.1111/imj.12070. Intern Med J. 2013. PMID: 23279565 Review.

9

Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus.

Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF. Vincent FB, et al. Among authors: morand ef. Lupus. 2013 Aug;22(9):873-84. doi: 10.1177/0961203313496302. Epub 2013 Jul 11. Lupus. 2013. PMID: 23846230

10

Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic.

Golder V, Connelly K, Staples M, Morand E, Hoi A. Golder V, et al. Among authors: morand e. Lupus. 2013 Nov;22(13):1425-30. doi: 10.1177/0961203313500547. Epub 2013 Aug 13. Lupus. 2013. PMID: 23942610

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

334 results

Search Page